A placebo-controlled phase 2 trial in moderate-to-advanced DKD patients suggested that selonsertib, which is an apoptosis signal-regulating kinase 1 (ASK1) inhibitor, might suppress the progression of DKD [128]. Here, MAP3K5 is linked to diabetic kidney disease.